Kanion Pharmaceutical
Modernizing traditional Chinese medicine through pharmaceutical R&D.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
| CNY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 20 % | 19 % | 12 % | (20 %) | 12 % | 12 % | 12 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 14 % | 15 % | 15 % | 16 % | 13 % | 13 % | 14 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 9 % | 10 % | 11 % | 10 % | 12 % | 14 % | 11 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 14 % | 14 % | 16 % | 16 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Jiangsu Kanion Pharmaceutical Co., Ltd. is a China-based pharmaceutical company founded in 1996 that integrates Traditional Chinese Medicine (TCM) with modern R&D, manufacturing, and sales. The company went public on the Shanghai Stock Exchange on September 18, 2002.
Kanion Pharmaceutical has established an innovative development model that combines TCM, chemical drugs, and biopharmaceuticals. The company's main product lines focus on therapeutic areas such as respiratory and infectious diseases, cardiovascular diseases, gynecology, and orthopedics. Representative products include Jin Zhen oral liquid, Ginkgo biloba diterpene glucamine injections, and Guizhi Fuling Capsules. The company is also developing chemical and biological drugs.
The business model relies on a combination of prescription drug sales in hospitals and clinics and over-the-counter (OTC) products sold through an extensive network of retail pharmacies. In 2022, sales through retail pharmacies accounted for over 50% of revenue. The company primarily operates in the domestic Chinese market. Kanion generates revenue from its core pharmaceutical sales, supplemented by health supplements. The company invests significantly in research and development, establishing national-level research platforms like the State Key Laboratory of New Technology of Pharmaceutical Process of Chinese Material Medica. One of its key products, the Guizhifuling capsule, completed Phase II clinical trials in the United States.
Keywords: Traditional Chinese Medicine, pharmaceutical manufacturing, biopharmaceuticals, drug R&D, respiratory diseases, cardiovascular drugs, gynecology treatments, orthopedics, OTC drugs, prescription medicine, Chinese pharmaceutical industry, herbal medicine, Jin Zhen, Guizhifuling, chemical drugs, public company, Shanghai Stock Exchange, clinical trials, health supplements, drug distribution.
